Molecular Formula | C6H12NO5P |
Molar Mass | 209.14 |
Density | 1.506±0.06 g/cm3(Predicted) |
Boling Point | 523.1±60.0 °C(Predicted) |
Solubility | H2O: ≥2mg/mL (warmed) |
Appearance | powder |
Color | white to beige |
pKa | 1.83±0.10(Predicted) |
Storage Condition | Desiccate at +4°C |
In vitro study | In the hippocampal slice in vitro, CGP 37849 selectively and reversibly antagonizes NMDA-evoked increases in CA1 pyramidal cell firing rate. In slices bathed in medium containing low Mg 2+ levels, concentrations of CGP 37849 up to 10 μM suppresses burst firing evoked in CA1 neurones by stimulation of Schaffer collateral-commissural fibres without affecting the magnitude of the initial population spike. |
In vivo study | CGP 37849 potently ( K i of 220 nM) and competitively inhibits NMDA-sensitive l-[ 3 H]-glutamate binding to postsynaptic density (PSD) fractins from rat brain. CGP 37849 inhibits the binding of the selective NMDA receptor antagonist, [ 3 H]-(±)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (CPP), with a K i of 35 nM. In vivo, oral administration to rats of CGP 37849 selectively blocks firing in hippocampal neurones induced by ionophoretically-applied NMDA, without affecting the responses to quisqualate or kainate. Oral administration to mice of CGP 37849 suppresses maximal electroshock-induced seizures in mice with an ED 50 of 21 mg/kg. |
Hazard Symbols | Xi - Irritant![]() |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
biological activity | CGP 37849 is a potent competitive orally active N-methyl-D-aspartate (NMDA) receptor antagonists. CGP 37849 is an anticonvulsant in rodents with antidepressant and anti-Anxiety effects. |